Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

Sponsors

If you want to go fast, go alone. If you want to go far, go together. We aim for long-term relationships with our partners and sponsors.

Read more

European Hematology Curriculum

Harmonization of hematology knowledge is part of EHA’s mission. The first step in harmonizing hematology training is to stipulate the required fields of knowledge, each with its recommended level of competence.

Read more

EHA Congratulates EHA Research Grants 2022 Recipients

The Hague, May 30, 2022 – EHA congratulates eight talented researchers in hematology on their receipt of the EHA Research Grants 2022 after a rigorous selection process.

Read more

Selected EMA news

March 2025New medicines recommended for approval
Lynozyfic (linvoseltamab) 
Treatment of refractory multiple myeloma (a cancer of the bone marrow)
New information on approved medicines 
Calquence (acalabrutinib) - new indication
Treatment of blood cancer

Columvi (glofitamab) - new indication
Treatment of blood cancer

Darzalex (daratumumab) - change of indication
Treatment…

Read more

Nomination Committee

Current committee members
Tony Green, United Kingdom (Chair)
Regular members
Maria Ester Bernardo, Italy
Jan Cools, Belgium
Sabine Eichinger, Austria
Shai Izraeli, Israel
Irene Roberts, United Kingdom
AimThe Nomination Committee (NC) is responsible for ensuring the quality of the EHA Board related to scientific and educational background, and balance…

Read more